Bio-Techne Reports Modest Growth in Final Quarter Ahead of $11.3 Billion Merck KGaA Acquisition
The life sciences company posted 3% organic revenue growth in Q4 fiscal 2026 while awaiting completion of its $73-per-share takeover deal.
Mixed Performance in Final Standalone Quarter
Bio-Techne Corporation reported fourth quarter fiscal 2026 results showing modest organic revenue growth of 3%, though reported revenue increased just 1% to $321.2 million (8-K filing, 2026-08-12). The Minneapolis-based life sciences company's full-year performance remained essentially flat, with both organic and reported revenue at $1.2 billion.
The quarter's financial performance comes as Bio-Techne awaits completion of its previously announced acquisition by Merck KGaA, Darmstadt, Germany, for $73 per share in cash—a transaction valued at approximately $11.3 billion in total enterprise value announced on June 25, 2026 (8-K filing, 2026-08-12).
Adjusted earnings per share declined marginally to $0.52 from $0.53 in the prior-year quarter, while GAAP EPS improved significantly to $0.35 from a loss of $(0.11), primarily due to a non-recurring impairment charge in the prior year (8-K filing, 2026-08-12). For the full fiscal year, adjusted EPS edged up to $1.93 from $1.92.
Segment Performance Diverges
The company's Protein Sciences segment, which supplies specialized proteins, immunoassays, and antibodies to biopharma and academic research communities, generated $231.2 million in fourth quarter sales, representing 2% growth and 1% organic growth (8-K filing, 2026-08-12). However, operating margin compressed to 42.0% from 43.6% in the prior-year period, impacted by "unfavorable volume and product mix" (8-K filing, 2026-08-12).
The Diagnostics and Spatial Biology segment showed stronger momentum, with organic revenue climbing 8% in the quarter despite flat reported sales of $90.1 million (8-K filing, 2026-08-12). The reported figure was affected by an 8% headwind from a business held-for-sale. Operating margin in this segment expanded notably to 11.2% from 6.0%, benefiting from the Exosome Diagnostics divestiture and ongoing profitability initiatives.
Conference Calls Discontinued
In light of the pending acquisition, Bio-Techne announced it "is no longer holding investor conference calls for quarterly results" (8-K filing, 2026-08-12). CEO Kim Kelderman stated the company "ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research and diagnostic workflows" (8-K filing, 2026-08-12).
MarginX data shows recent insider activity including options exercises by James Hippel totaling 62,068 shares on two occasions, with 51,024 shares withheld for taxes.
Adjusted operating margin expanded slightly to 32.2% from 32.0% in the fourth quarter, supported by profitability initiatives and the Exosome divestiture, though partially offset by unfavorable product mix (8-K filing, 2026-08-12). Full-year adjusted operating income rose 1% to $386.1 million.
The company, which operates in 34 locations globally and employs approximately 3,000 people, serves academic researchers, biopharmaceutical companies, and clinical diagnostic laboratories with more than 500,000 products (8-K filing, 2026-08-12).
This article was generated by MarginX from the 8-K filing on 2026-08-12. It is not investment advice.